New drug approved to treat HIV-1

(HealthDay)—Tivicay (dolutegravir) has been approved by the U.S. Food and Drug Administration to treat infection with HIV-1, a strain of the virus that causes AIDS.

The drug, among a class called integrase strand transfer inhibitors, interferes with an enzyme that HIV needs to multiply. It's been approved in combination with other and for people aged 12 and older who weigh at least 40 kilograms (approximately 88 pounds), the FDA said in a news release.

Some 50,000 Americans acquire HIV infection each year, and about 15,500 people died from the disease in 2010, the agency said, citing the U.S. Centers for Disease Control and Prevention.

The drug's safety and effectiveness were evaluated in clinical studies involving more than 2,500 adults and children, the FDA said. The most common side effects included difficulty sleeping, headache and more serious problems including allergic-like reactions and abnormal liver function in people who had hepatitis B or C.

Tivicay is produced by GlaxoSmithKline, based in Research Triangle Park, N.C.

More information: The U.S. Department of Health and Human Services's AIDS.gov website has more about HIV/AIDS.

add to favorites email to friend print save as pdf

Related Stories

New test IDs genotype of hepatitis C

Jun 20, 2013

(HealthDay)—A new test to help doctors identify the genotype of a person's hepatitis C infection has been approved by the U.S. Food and Drug Administration.

Simponi approved for ulcerative colitis

May 15, 2013

(HealthDay)—Simponi (golimumab) injection has been approved by the U.S. Food and Drug Administration to treat adults with moderate-to-severe ulcerative colitis.

Vibativ approved for certain bacterial pneumonia

Jun 24, 2013

(HealthDay)—The antibiotic Vibativ (telavancin) has been approved by the U.S. Food and Drug Administration to treat pneumonia caused by Staphylococcus aureus bacteria when other treatments aren't suitable.

Recommended for you

Clinical trial of herpes vaccine now enrolling patients

Jul 28, 2014

Creating a successful vaccine against two members of the family, the sexually transmitted herpes simplex virus 1 (HSV-1) and 2 (HSV-2), has proven to be challenging. A clinical trial being conducted by a ...

How we got ahead in HIV control

Jul 25, 2014

When AIDS first emerged in the early 1980s, HIV infection was a death sentence. But a global effort has ensured this is no longer the case for a growing number of people.

User comments